Nov 07, 2016 7:00am EST Can-Fite to Participate in BIO-Europe Partnering Conference on November 7-9, 2016 in Cologne, Germany
Nov 01, 2016 7:00am EDT Can-Fite Advances Towards a Pivotal Phase III Clinical Trial in Psoriasis with Piclidenoson (CF101) Following Reaching Agreement with EMA
Oct 13, 2016 7:00am EDT Can-Fite Submits Protocol for Phase II Trial of CF102 in the Treatment of NAFLD/NASH
Sep 20, 2016 7:00am EDT Can-Fite Reports New Data on CF102's Liver Protective & Regenerative Properties Published in Scientific Journal
Sep 13, 2016 7:00am EDT Can-Fite Receives Notice of Allowance for Psoriasis Patent in Europe Ahead of Phase III Trial
Sep 07, 2016 7:00am EDT Can-Fite to Present at Rodman & Renshaw Conference in New York City on September 12, 2016
Aug 08, 2016 7:00am EDT Can-Fite's Phase II/III Psoriasis Study Results Published in Journal of Drugs in Dermatology
Jul 25, 2016 7:00am EDT Can-Fite Completes Phase II Study Design for CF102 in the Treatment of NASH/NAFLD
